P53 tumor suppressor gene therapy for cancer

ONCOLOGY

Volumn 13, Issue 10 SUPPL. 5, 1999, Pages 148-154

  Roth, Jack A ^a   Swisher, Stephen G ^a   Meyn, Raymond E ^b  

^a Department of Thoracic and Cardiovascular Surgery ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ANIMAL; APOPTOSIS; CELL CYCLE; CLINICAL TRIAL; DRUG EFFECT; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; RADIATION EXPOSURE; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE EXPRESSION; GENE THERAPY; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 0033212143     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Anderson WF: Human gene therapy. Science 256:808-813, 1992.
2. Blaese RM, Culver KW, Miller AD, et al: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270:475-480, 1995.
3. Culver KW, Ram Z, Wallbridge S, et al: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552, 1992.
4. Bishop JM: Molecular themes in oncogenesis. Cell 64:235-248, 1991.
5. Weinberg RA: Tumor suppressor genes. Science 254:1138-1146, 1991.
6. Weinberg RA: Oncogenes and tumor suppressor genes. CA Cancer J Clin 44:160-170, 1994.
7. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79, 1990.
8. Baker SJ, Markowitz S, Fearon ER, et al: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915, 1990.
9. Mukhopadhyay T, Cavender A, Tainsky M, et al: Expression of antisense k-ras message in a human lung cancer cell line with a spontaneous activated k-ras oncogene alters the transformed phenotype (abstract 1799). Proc Am Assoc Cancer Res 31:304-304, 1990.
10. Takahashi T, Carbone D, Takahashi T, et al: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992.
11. Bookstein R, Shew JY, Chen PL, et al: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715, 1990.
12. Alemany R, Ruan S, Kataoka M, et al: Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther 3:296-301, 1996.
13. Chen PL, Scully P, Shew JY, et al: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198, 1989.
14. Kaelin WG Jr, Pallas DC, DeCaprio JA, et al: Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64:521-532, 1991.
15. Eastham JA, Hall SJ, Sehgal I, et al: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155, 1995.
16. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993.
17. el-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.